198 related articles for article (PubMed ID: 15717138)
1. Angiotensin II-receptor antagonist losartan does not prevent nitroglycerin tolerance in patients with coronary artery disease.
Longobardi G; Ferrara N; Leosco D; Abete P; Furgi G; Cacciatore F; Corbi G; Pescatore R; Rengo F
Cardiovasc Drugs Ther; 2004 Sep; 18(5):363-70. PubMed ID: 15717138
[TBL] [Abstract][Full Text] [Related]
2. The effect of supplemental L-arginine on tolerance development during continuous transdermal nitroglycerin therapy.
Parker JO; Parker JD; Caldwell RW; Farrell B; Kaesemeyer WH
J Am Coll Cardiol; 2002 Apr; 39(7):1199-203. PubMed ID: 11923046
[TBL] [Abstract][Full Text] [Related]
3. Effect of losartan in treatment of exercise-induced myocardial ischemia.
Longobardi G; Corbi G; Cacciatore F; Abete P; Furgi G; Vitale DF; Rengo F; Ferrara N
Am J Cardiol; 2007 Nov; 100(10):1517-21. PubMed ID: 17996511
[TBL] [Abstract][Full Text] [Related]
4. The effect of hydralazine on the development of tolerance to continuous nitroglycerin.
Parker JD; Parker AB; Farrell B; Parker JO
J Pharmacol Exp Ther; 1997 Feb; 280(2):866-75. PubMed ID: 9023301
[TBL] [Abstract][Full Text] [Related]
5. Effects of intermittent transdermal nitroglycerin on occurrence of ischemia after patch removal: results of the second transdermal intermittent dosing evaluation study (TIDES-II).
Pepine CJ; Lopez LM; Bell DM; Handberg-Thurmond EM; Marks RG; McGorray S
J Am Coll Cardiol; 1997 Oct; 30(4):955-61. PubMed ID: 9316524
[TBL] [Abstract][Full Text] [Related]
6. The angiotensin II-receptor antagonist losartan does not prevent hemodynamic or vascular tolerance to nitroglycerin.
Milone SD; Azevedo ER; Forster C; Parker JD
J Cardiovasc Pharmacol; 1999 Nov; 34(5):645-50. PubMed ID: 10547079
[TBL] [Abstract][Full Text] [Related]
7. Effects of diuretic therapy on the development of tolerance to nitroglycerin and exercise capacity in patients with chronic stable angina.
Parker JD; Parker AB; Farrell B; Parker JO
Circulation; 1996 Feb; 93(4):691-6. PubMed ID: 8640997
[TBL] [Abstract][Full Text] [Related]
8. Attenuation of nitrate tolerance and oxidative stress by an angiotensin II receptor blocker in patients with coronary spastic angina.
Hirai N; Kawano H; Yasue H; Shimomura H; Miyamoto S; Soejima H; Kajiwara I; Sakamoto T; Yoshimura M; Nakamura H; Yodoi J; Ogawa H
Circulation; 2003 Sep; 108(12):1446-50. PubMed ID: 12952843
[TBL] [Abstract][Full Text] [Related]
9. Chronic effects of transdermal nitroglycerin in stable angina pectoris: a within-patient, placebo-controlled study.
Gibelli G; Negrini M; Bruno AM; Fiorini GL; Lambiase M; Magenta G; Corti D; Prina L; Pollavini PG; De Ponti C
Int J Clin Pharmacol Ther Toxicol; 1989 Sep; 27(9):436-41. PubMed ID: 2509380
[TBL] [Abstract][Full Text] [Related]
10. Intermittent transdermal nitroglycerin therapy. Decreased anginal threshold during the nitrate-free interval.
Parker JD; Parker AB; Farrell B; Parker JO
Circulation; 1995 Feb; 91(4):973-8. PubMed ID: 7850984
[TBL] [Abstract][Full Text] [Related]
11. Treatment of hypertension associated with stable angina pectoris: favourable interaction between new metoprolol formulation (OROS) and nifedipine.
Di Somma S; de Divitiis M; Bertocchi F; Carotenuto A; Cudemo G; Petitto M; Napodano M; de Divitiis O
Cardiologia; 1996 Jul; 41(7):635-43. PubMed ID: 8831181
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of transdermal nitroglycerin patches evaluated by dipyridamole-induced myocardial ischemia in patients with coronary artery disease. Comparison between continuous and intermittent schedule.
Longobardi G; Ferrara N; Abete P; Leosco D; Furgi G; Nicolino A; Vitale DF; Rengo F
Cardiovasc Drugs Ther; 2002 Dec; 16(6):535-42. PubMed ID: 12766388
[TBL] [Abstract][Full Text] [Related]
13. Folic acid prevents nitroglycerin-induced nitric oxide synthase dysfunction and nitrate tolerance: a human in vivo study.
Gori T; Burstein JM; Ahmed S; Miner SE; Al-Hesayen A; Kelly S; Parker JD
Circulation; 2001 Sep; 104(10):1119-23. PubMed ID: 11535566
[TBL] [Abstract][Full Text] [Related]
14. Comparison of buccal nitroglycerin and oral isosorbide dinitrate for nitrate tolerance in stable angina pectoris.
Parker JO; Vankoughnett KA; Farrell B
Am J Cardiol; 1985 Nov; 56(12):724-8. PubMed ID: 3933317
[TBL] [Abstract][Full Text] [Related]
15. Antianginal efficacy of a new nitroglycerin patch.
Parker JO
Eur Heart J; 1989 May; 10 Suppl A():43-9. PubMed ID: 2501094
[TBL] [Abstract][Full Text] [Related]
16. [Development of tolerance with regard to the anti-ischemic effect of isosorbide dinitrate in regular multiple daily administration].
Reiniger G; Blasini R; Brügmann U; Rudolph W
Herz; 1984 Jun; 9(3):146-52. PubMed ID: 6430768
[TBL] [Abstract][Full Text] [Related]
17. Oral nitroglycerin as a prophylactic antianginal drug: clinical, physiologic, and statistical evidence of efficacy based on a three-phase experimental design.
Winsor T; Berger HJ
Am Heart J; 1975 Nov; 90(5):611-26. PubMed ID: 811102
[TBL] [Abstract][Full Text] [Related]
18. Effects of dosing intervals on the development of tolerance to high dose transdermal nitroglycerin.
Nabel EG; Barry J; Rocco MB; Mead K; Selwyn AP
Am J Cardiol; 1989 Mar; 63(11):663-9. PubMed ID: 2493732
[TBL] [Abstract][Full Text] [Related]
19. A randomized placebo controlled, double-blind, crossover trial of transdermal nitroglycerin in stable angina pectoris.
Rezaković DE; Pavicić L; Majacić M
Eur Heart J; 1988 Jan; 9 Suppl A():73-81. PubMed ID: 3137073
[TBL] [Abstract][Full Text] [Related]
20. Intermittent transdermal nitroglycerin therapy in angina pectoris. Clinically effective without tolerance or rebound. Minitran Efficacy Study Group.
Parker JO; Amies MH; Hawkinson RW; Heilman JM; Hougham AJ; Vollmer MC; Wilson RR
Circulation; 1995 Mar; 91(5):1368-74. PubMed ID: 7867175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
